<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03896230</url>
  </required_header>
  <id_info>
    <org_study_id>Pro2018-0970</org_study_id>
    <nct_id>NCT03896230</nct_id>
  </id_info>
  <brief_title>Ketamine for Pain in the Emergency Department</brief_title>
  <official_title>Comparison of Ketamine 0.1 mg/kg, 0.2 mg/kg, and 0.3 mg/kg Intravenous Doses for Acute Pain in the Emergency Department: A Prospective, Randomized, Double-blind, Active-controlled, Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hackensack Meridian Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hackensack Meridian Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will prospectively compare the mean Numerical Rating Scale (NRS) pain score
      reduction amongst three recommended dosing strategies of intravenous ketamine (0.1 mg/kg, 0.2
      mg/kg, and 0.3mg/kg) for acute pain in the emergency department (ED).This study will also
      examine the frequency of adverse events secondary to ketamine including fatigue, dizziness,
      nausea, headache, feeling of unreality, changes in hearing or vision, mood changes,
      generalized discomfort, and hallucinations, changes in vital signs. Subgroups for exploratory
      analysis based on the need for rescue analgesia within two hours of ketamine administration,
      adequate pain relief, previous opioid tolerance, and age (adults &lt; 65 years old and &gt; 65
      years old).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A literature review was performed that searched for randomized clinical trials involving
      ketamine IV boluses for acute pain in the Emergency Department. Studies involving continuous
      infusions or intranasal routes of ketamine administration were not included. Thirteen
      randomized clinical trials were identified meeting this criteria. None of these trials
      directly compared ketamine doses within the 0.1-0.3 mg/kg range for pain score reduction and
      adverse events. Many of these trials concluded with the recommendation that further studies
      were needed to evaluate the optimal dosing of ketamine for acute pain and determine which
      populations are most ideal for its use. This study will be the first to evaluate ketamine for
      acute pain in the emergency department at standard of care doses (0.1 mg/kg, 0.2 mg/kg, and
      0.3 mg/kg IV) to determine which dose correlates with the most efficacy and safety.

      This study will include the following procedures:

        -  Patient consent, screening, and enrollment will be performed by the treating resident or
           attending who will remain blinded

        -  Patient will be assigned a subject number

        -  Treating resident or attending will notify the ED pharmacist that a patient has been
           enrolled in the trial

        -  ED pharmacist will notify the IV room and place the study drug order

        -  Either the ED pharmacist or a pharmacy supervisor will randomize the subject based on
           the predetermined randomization list

        -  Study drug will be prepared as 0.1 mg/kg, 0.2 mg/kg, or 0.3 mg/kg IV dose in a 100 mL
           solution of dextrose 5% or sodium chloride 0.9%

        -  ED pharmacist will promptly deliver the study drug to the ED

        -  Baseline vital signs will be assessed prior to starting the study drug infusion

        -  Study drug will be administered via IV infusion over 20 minutes

        -  Treating resident or attending will reassess the patient at 15 minutes from the end of
           infusion, at 30 minutes from the end of infusion, and then every 30 minutes for up to
           120 minutes or until discharge, whichever is sooner
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 3, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>3 arms each arm getting a different dose of ketamine</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-blinded study (only the pharmacist supervisor that has no other involvement with the study will know the dose)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Pain score</measure>
    <time_frame>2 hours post infusion completion</time_frame>
    <description>Pain score using Numerical Rating Scale (NRS) post ketamine infusion. The Numerical Rating Scale (NRS) ranges from 0-to-10 with 0 being no pain and lower numbers representing less pain, so in this case lower numbers will represent better outcomes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>2 hours post infusion completion</time_frame>
    <description>Frequency of adverse events secondary to ketamine including fatigue, dizziness, nausea, headache, feeling of unreality, changes in hearing or vision, mood changes, generalized discomfort, and hallucinations, changes in vital signs.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Acute Pain</condition>
  <arm_group>
    <arm_group_label>Arm 1: 0.1 mg/kg ketamine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.1 mg/kg in a 100 mL solution of dextrose 5% or sodium chloride 0.9% will be give after patient consent and enrollment in the study, vitals are followed (heart rate, systolic blood pressure and respiratory rate) for 2 hours following completion of ketamine infusion. Evaluated for side effects for 2 hours following completion of ketamine infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 1: 0.2 mg/kg ketamine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.2 mg/kg in a 100 mL solution of dextrose 5% or sodium chloride 0.9% will be give after patient consent and enrollment in the study, vitals are followed (heart rate, systolic blood pressure and respiratory rate) for 2 hours following completion of ketamine infusion. Evaluated for side effects for 2 hours following completion of ketamine infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 1: 0.3 mg/kg ketamine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.3 mg/kg in a 100 mL solution of dextrose 5% or sodium chloride 0.9% will be give after patient consent and enrollment in the study, vitals are followed (heart rate, systolic blood pressure and respiratory rate) for 2 hours following completion of ketamine infusion. Evaluated for side effects for 2 hours following completion of ketamine infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine Injectable Product</intervention_name>
    <description>Three different doses of ketamine will be administered.</description>
    <arm_group_label>Arm 1: 0.1 mg/kg ketamine</arm_group_label>
    <arm_group_label>Arm 1: 0.2 mg/kg ketamine</arm_group_label>
    <arm_group_label>Arm 1: 0.3 mg/kg ketamine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute pain (including acute on chronic pain)

          -  Pain score of moderate to severe (&gt; 4/10) on the Numerical Rating Scale

          -  Provider determines the patient requires intravenous ketamine for analgesia

        Exclusion Criteria:

          -  History of hypersensitivity to ketamine

          -  Altered mental status

          -  Psychiatric illness

          -  Known history of renal or hepatic insufficiency

          -  Acute head or eye injury

          -  Suspected intracranial hypertension or mass

          -  Headache as the chief complaint

          -  Alcohol or drug abuse

          -  Received an analgesic within the last four hours

          -  History of congestive heart failure

          -  History of aortic or brain aneurysm

          -  Active Chest Pain

          -  Porphyria

          -  Active methadone treatment

          -  Pregnant or breastfeeding

          -  Signs of respiratory, hemodynamic, or neurologic compromise

               -  Systolic blood pressure &lt; 90 mmHg or &gt; 180 mmHg

               -  Heart rate &lt; 50 beats per minute or &gt; 150 beats per minute

               -  Respiratory rate &lt; 10 breaths per minute or &gt; 30 breaths per minute

               -  Glasgow Coma Score &lt; 15

          -  Previously received ketamine &lt; 0.3 mg/kg IV for acute pain in the emergency department
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Todd KH, Ducharme J, Choiniere M, Crandall CS, Fosnocht DE, Homel P, Tanabe P; PEMI Study Group. Pain in the emergency department: results of the pain and emergency medicine initiative (PEMI) multicenter study. J Pain. 2007 Jun;8(6):460-6. Epub 2007 Feb 15.</citation>
    <PMID>17306626</PMID>
  </reference>
  <reference>
    <citation>2. American College of Emergency Physicians Policy Statement. Optimizing the treatment of acute pain in the emergency department. Ann Emerg Med. 2017;70:446-8.</citation>
  </reference>
  <reference>
    <citation>Pourmand A, Mazer-Amirshahi M, Royall C, Alhawas R, Shesser R. Low dose ketamine use in the emergency department, a new direction in pain management. Am J Emerg Med. 2017 Jun;35(6):918-921. doi: 10.1016/j.ajem.2017.03.005. Epub 2017 Mar 2. Review.</citation>
    <PMID>28285863</PMID>
  </reference>
  <reference>
    <citation>4. Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. Highlights of the 2011 Drug Abuse Warning Network (DAWN) findings on drug-related emergency department visits. 2013. Rockville, MD.</citation>
  </reference>
  <reference>
    <citation>Rudd RA, Aleshire N, Zibbell JE, Gladden RM. Increases in Drug and Opioid Overdose Deaths--United States, 2000-2014. MMWR Morb Mortal Wkly Rep. 2016 Jan 1;64(50-51):1378-82. doi: 10.15585/mmwr.mm6450a3.</citation>
    <PMID>26720857</PMID>
  </reference>
  <reference>
    <citation>Andolfatto G, Willman E, Joo D, Miller P, Wong WB, Koehn M, Dobson R, Angus E, Moadebi S. Intranasal ketamine for analgesia in the emergency department: a prospective observational series. Acad Emerg Med. 2013 Oct;20(10):1050-4. doi: 10.1111/acem.12229.</citation>
    <PMID>24127709</PMID>
  </reference>
  <reference>
    <citation>Gorlin AW, Rosenfeld DM, Ramakrishna H. Intravenous sub-anesthetic ketamine for perioperative analgesia. J Anaesthesiol Clin Pharmacol. 2016 Apr-Jun;32(2):160-7. doi: 10.4103/0970-9185.182085. Review.</citation>
    <PMID>27275042</PMID>
  </reference>
  <reference>
    <citation>Scheppke KA, Braghiroli J, Shalaby M, Chait R. Prehospital use of i.m. ketamine for sedation of violent and agitated patients. West J Emerg Med. 2014 Nov;15(7):736-41. doi: 10.5811/westjem.2014.9.23229. Epub 2014 Nov 11.</citation>
    <PMID>25493111</PMID>
  </reference>
  <reference>
    <citation>Motov S, Mann S, Drapkin J, Butt M, Likourezos A, Yetter E, Brady J, Rothberger N, Gohel A, Flom P, Mai M, Fromm C, Marshall J. Intravenous subdissociative-dose ketamine versus morphine for acute geriatric pain in the Emergency Department: A randomized controlled trial. Am J Emerg Med. 2019 Feb;37(2):220-227. doi: 10.1016/j.ajem.2018.05.030. Epub 2018 May 16.</citation>
    <PMID>29807629</PMID>
  </reference>
  <reference>
    <citation>Beaudoin FL, Lin C, Guan W, Merchant RC. Low-dose ketamine improves pain relief in patients receiving intravenous opioids for acute pain in the emergency department: results of a randomized, double-blind, clinical trial. Acad Emerg Med. 2014 Nov;21(11):1193-202. doi: 10.1111/acem.12510.</citation>
    <PMID>25377395</PMID>
  </reference>
  <reference>
    <citation>Motov S, Rockoff B, Cohen V, Pushkar I, Likourezos A, McKay C, Soleyman-Zomalan E, Homel P, Terentiev V, Fromm C. Intravenous Subdissociative-Dose Ketamine Versus Morphine for Analgesia in the Emergency Department: A Randomized Controlled Trial. Ann Emerg Med. 2015 Sep;66(3):222-229.e1. doi: 10.1016/j.annemergmed.2015.03.004. Epub 2015 Mar 26.</citation>
    <PMID>25817884</PMID>
  </reference>
  <reference>
    <citation>12. American College of Emergency Physicians. &quot;Sub-Dissociative Ketamine for Analgesia&quot;. Policy Resource and Education Paper. November 2017.</citation>
  </reference>
  <reference>
    <citation>Schwenk ES, Viscusi ER, Buvanendran A, Hurley RW, Wasan AD, Narouze S, Bhatia A, Davis FN, Hooten WM, Cohen SP. Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Acute Pain Management From the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists. Reg Anesth Pain Med. 2018 Jul;43(5):456-466. doi: 10.1097/AAP.0000000000000806.</citation>
    <PMID>29870457</PMID>
  </reference>
  <reference>
    <citation>Abbasi S, Bidi N, Mahshidfar B, Hafezimoghadam P, Rezai M, Mofidi M, Farsi D. Can low-dose of ketamine reduce the need for morphine in renal colic? A double-blind randomized clinical trial. Am J Emerg Med. 2018 Mar;36(3):376-379. doi: 10.1016/j.ajem.2017.08.026. Epub 2017 Aug 14.</citation>
    <PMID>28821365</PMID>
  </reference>
  <reference>
    <citation>Bowers KJ, McAllister KB, Ray M, Heitz C. Ketamine as an Adjunct to Opioids for Acute Pain in the Emergency Department: A Randomized Controlled Trial. Acad Emerg Med. 2017 Jun;24(6):676-685. doi: 10.1111/acem.13172. Epub 2017 Mar 22.</citation>
    <PMID>28177167</PMID>
  </reference>
  <reference>
    <citation>Clattenburg EJ, Hailozian C, Haro D, Yoo T, Flores S, Louie D, Herring AA. Slow Infusion of Low-dose Ketamine Reduces Bothersome Side Effects Compared to Intravenous Push: A Double-blind, Double-dummy, Randomized Controlled Trial. Acad Emerg Med. 2018 Sep;25(9):1048-1052. doi: 10.1111/acem.13428. Epub 2018 May 25.</citation>
    <PMID>29645317</PMID>
  </reference>
  <reference>
    <citation>Galinski M, Dolveck F, Combes X, Limoges V, Sma√Øl N, Pommier V, Templier F, Catineau J, Lapostolle F, Adnet F. Management of severe acute pain in emergency settings: ketamine reduces morphine consumption. Am J Emerg Med. 2007 May;25(4):385-90.</citation>
    <PMID>17499654</PMID>
  </reference>
  <reference>
    <citation>Jahanian F, Hosseininejad SM, Amini Ahidashti H, Bozorgi F, Goli Khatir I, Montazar SH, Azarfar V. Efficacy and Safety of Morphine and Low Dose Ketamine for Pain Control of Patients with Long Bone Fractures: A Randomized, Double-Blind, Clinical Trial. Bull Emerg Trauma. 2018 Jan;6(1):31-36. doi: 10.29252/beat-060105.</citation>
    <PMID>29379807</PMID>
  </reference>
  <reference>
    <citation>Mahshidfar B, Mofidi M, Fattahi M, Farsi D, Hafezi Moghadam P, Abbasi S, Rezai M. Acute Pain Management in Emergency Department, Low Dose Ketamine Versus Morphine, A Randomized Clinical Trial. Anesth Pain Med. 2017 Dec 26;7(6):e60561. doi: 10.5812/aapm.60561. eCollection 2017 Dec.</citation>
    <PMID>29696126</PMID>
  </reference>
  <reference>
    <citation>Majidinejad S, Esmailian M, Emadi M. Comparison of Intravenous Ketamine with Morphine in Pain Relief of Long Bones Fractures: a Double Blind Randomized Clinical Trial. Emerg (Tehran). 2014 Spring;2(2):77-80.</citation>
    <PMID>26495351</PMID>
  </reference>
  <reference>
    <citation>Miller JP, Schauer SG, Ganem VJ, Bebarta VS. Low-dose ketamine vs morphine for acute pain in the ED: a randomized controlled trial. Am J Emerg Med. 2015 Mar;33(3):402-8. doi: 10.1016/j.ajem.2014.12.058. Epub 2015 Jan 7.</citation>
    <PMID>25624076</PMID>
  </reference>
  <reference>
    <citation>Motov S, Mai M, Pushkar I, Likourezos A, Drapkin J, Yasavolian M, Brady J, Homel P, Fromm C. A prospective randomized, double-dummy trial comparing IV push low dose ketamine to short infusion of low dose ketamine for treatment of pain in the ED. Am J Emerg Med. 2017 Aug;35(8):1095-1100. doi: 10.1016/j.ajem.2017.03.004. Epub 2017 Mar 3.</citation>
    <PMID>28283340</PMID>
  </reference>
  <reference>
    <citation>Sin B, Tatunchak T, Paryavi M, Olivo M, Mian U, Ruiz J, Shah B, de Souza S. The Use of Ketamine for Acute Treatment of Pain: A Randomized, Double-Blind, Placebo-Controlled Trial. J Emerg Med. 2017 May;52(5):601-608. doi: 10.1016/j.jemermed.2016.12.039. Epub 2017 Mar 6.</citation>
    <PMID>28279542</PMID>
  </reference>
  <reference>
    <citation>24. Ketalar [package insert]. Chestnut Ridge, NY. Par Pharmaceutical.</citation>
  </reference>
  <reference>
    <citation>25. Food and Drug Administration (FDA). Extended-release (ER) and long-acting (LA) opioid analgesics Risk Evaluation and Mitigation Strategy (REMS). www.fda.gov/downloads/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm311290.pdf. Accessed September 20th, 2018.</citation>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 28, 2019</study_first_submitted>
  <study_first_submitted_qc>March 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2019</study_first_posted>
  <last_update_submitted>March 9, 2020</last_update_submitted>
  <last_update_submitted_qc>March 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>moderate to severe pain</keyword>
  <keyword>emergency department patient</keyword>
  <keyword>ketamine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emergencies</mesh_term>
    <mesh_term>Acute Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>All study related materials will be kept confidential as required by law. Written documentation and computer files will remain in a locked or password protected location, with access given to those directly responsible for the conduct of the study. In addition, all information will be recorded in such a manner that subjects whose data is included in the analysis cannot be identified directly or through identifiers linked to the subjects.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

